Aclaris Therapeutics (ACRS) Research & Development (2017 - 2025)
Historic Research & Development for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $13.0 million.
- Aclaris Therapeutics' Research & Development rose 11873.74% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.1 million, marking a year-over-year decrease of 1194.98%. This contributed to the annual value of $33.6 million for FY2024, which is 6586.23% down from last year.
- Per Aclaris Therapeutics' latest filing, its Research & Development stood at $13.0 million for Q3 2025, which was up 11873.74% from $11.4 million recorded in Q2 2025.
- Aclaris Therapeutics' Research & Development's 5-year high stood at $26.6 million during Q4 2023, with a 5-year trough of $6.0 million in Q3 2024.
- For the 5-year period, Aclaris Therapeutics' Research & Development averaged around $15.2 million, with its median value being $14.0 million (2021).
- As far as peak fluctuations go, Aclaris Therapeutics' Research & Development skyrocketed by 13779.92% in 2022, and later plummeted by 7505.44% in 2024.
- Aclaris Therapeutics' Research & Development (Quarter) stood at $14.1 million in 2021, then surged by 49.43% to $21.1 million in 2022, then rose by 26.45% to $26.6 million in 2023, then crashed by 66.13% to $9.0 million in 2024, then soared by 44.34% to $13.0 million in 2025.
- Its last three reported values are $13.0 million in Q3 2025, $11.4 million for Q2 2025, and $11.6 million during Q1 2025.